Dyne Therapeutics (DYN) Income towards Parent Company (2019 - 2026)

Dyne Therapeutics' Income towards Parent Company history runs 8 years deep, the most recent figure standing at -$116.5 million for Q1 2026.

• In Q1 2026, Income towards Parent Company fell 1.08% year-over-year to -$116.5 million; the TTM figure through Mar 2026 stood at -$442.6 million (down 20.92% YoY), while the FY2025 annual figure was -$438.3 million, down 38.29% from the prior year.
• Income towards Parent Company was -$116.5 million for Q1 2026 at Dyne Therapeutics, down from -$108.5 million in the prior quarter.
• In the past five years, Income towards Parent Company ranged from a high of -$35.6 million in Q1 2022 to a low of -$116.5 million in Q1 2026.
• Historically, Income towards Parent Company has averaged -$75.1 million across 5 years, with a median of -$65.9 million in 2023.
• Biggest YoY gain for Income towards Parent Company was 25.06% in 2022; the steepest drop was 74.64% in 2022.
• A 5-year view of Income towards Parent Company shows it stood at -$38.8 million in 2022, then slumped by 69.93% to -$65.9 million in 2023, then plunged by 35.76% to -$89.5 million in 2024, then retreated by 21.18% to -$108.5 million in 2025, then dropped by 7.42% to -$116.5 million in 2026.
• The last three Income towards Parent Company figures came in at -$116.5 million (Q1 2026), -$108.5 million (Q4 2025), and -$108.3 million (Q3 2025), per Business Quant data.